尼妥珠单抗联合多西他赛—顺铂—氟尿嘧啶治疗晚期转移性头颈部鳞癌的疗效

Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil in the treatment of advanced metastatic head and neck squamous cell carcinoma

目的观察尼妥珠单抗联合多西他赛—顺铂—氟尿嘧啶治疗晚期转移性头颈部鳞癌的疗效。方法选取2017年5月-2018年5月于福建医科大学附属漳州市医院经病理检查确诊的晚期转移性头颈部鳞癌患者47例,所有患者予尼妥珠单抗联合多西他赛—顺铂—氟尿嘧啶治疗,观察患者的疗效及不良反应,出院随访2年,观察患者2年内生存情况。结果肿瘤获得完全缓解16例(34.04%),部分缓解24例(51.06%),总有效率为85.11%;3级白细胞减少发生率为38.30%(18/47)。出院随访2年,无进展生存患者有34例,生存率为72.34%,总生存患者37例,总生存率78.72%。结论尼妥珠单抗联合多西他赛—顺铂—氟尿嘧啶治疗晚期转移性头颈部鳞癌的疗效较好,可确保患者用药安全,在控制病情进展的同时延长患者的生存期,值得临床大力推广并应用。

Objective To observe the efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil in the treatment of advanced metastatic head and neck squamous cell carcinoma.Methods A total of 47 patients with advanced metastatic head and neck squamous cell carcinoma diagnosed by pathological examination in Zhangzhou Affiliated Hospital of Fujian Medical University from May 2017 to May 2018 were selected,all patients were treated with nimotuzumab combined with docetaxel-cisplatin-fluorouracil treatment,the efficacy and adverse reactions of the patients were observed.Followed up for 2 years after discharge from the hospital,and the survival status of the patients within 2 years was observed.Results 16 cases(34.04%)had complete remission,and 24 cases(51.06%)had partial remission,the total effective rate was 85.11%.The incidence of grade 3 leukopenia was 38.30%(18/47).After discharge for 2 years,there were 34 patients with progression-free survival,with a survival rate of 72.34%,and 37 patients with overall survival,with an overall survival rate of 78.72%.Conclusion Nimotuzumab combined with docetaxel-cisplatin-fluorouracil has a better effect in the treatment of advanced metastatic head and neck squamous cell carcinoma,which can ensure the safety of patients′medication,and prolong the survival time of patients while controlling the progress of the disease,which is worthy of clinical promotion and application.